According to a release from the Company, Prolia is the first approved therapy that specifically targets RANK Ligand, an essential regulator of bone-removing cells (osteoclasts). Data were presented at the American Society for Bone and Mineral ... Individual.com, 1 month ago
Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® Denosumab In Postmenopausal Women... - 4 Traders, 1 month ago
Amgen updates on Prolia in postmenopausal osteoporosis16-09-2014 - Pharma Letter, 1 month ago
1 images for "amgen rank"
Amgen ( AMGN ) shares gained 6.1% immediately after the company held a business review meeting and provided a comprehensive overview of its initiatives geared towards growth objectives, and strategic and capital allocation plans. Amgen also provided ...Yahoo! Finance, 20 hours ago
Amgen ( AMGN ) reported third quarter 2014 earnings of $2.30 per share, well above the Zacks Consensus Estimate of $2.06 and the year-ago earnings of $1.93. Earnings were driven by higher revenues and higher profitability on Enbrel. [embedded ...Yahoo! Finance, 2 days ago
Earlier today, the world's largest biotechnology company, Amgen Inc. ( AMGN ) reported its earnings results for fiscal Q3 after the closing bell, and the company posted better than anticipated earnings and revenue, despite the fact that the ...Yahoo! Finance, 2 days ago
More from: , Investing.com...and 1 other sources
Summary Amgen and Regeneron are the two companies that have filed for marketing approval for their drugs to lower cholesterol via the PCSK9 pathway. Each company has numerous strengths. Recent data have given additional force to the uptrends of ...Seeking Alpha, 1 week ago Amgen Sues Sanofi and Regeneron over PCSK9 Candidate Yahoo! Finance, 1 week ago
(REUTERS) Hedge fund manager Daniel Loeb told investors on Tuesday he urged U.S. biotechnology company Amgen Inc to split into two separate businesses, a move he said could boost its share price by more than 80 percent. Our own extensive ...Fortune, 1 week ago UPDATE 2-Third Point's Loeb urges breakup of biotech company Amgen CNBC, 1 week ago Loeb's hedge fund Third Point bets on eBay, Amgen, Alibaba, exits Sony GlobalPost, 1 week ago Third Point's Loeb urges breakup of biotech company Amgen Yahoo! Finance, 1 week ago
Today, Zacks is promoting its ''Buy'' stock recommendations. . Here are highlights from Wednesday's Analyst Blog: Biotech Stock Roundup It was all about earnings last week with several biotech companies reporting third quarter results. While it ...Wall Street Select, 1 hour ago THE ZACKS ANALYST BLOG HIGHLIGHTS : Celgene, Biogen, Alexion, Cubist and Amgen 4 Traders, 1 hour ago The Zacks Analyst Blog Highlights: AbbVie, Amgen, Regeneron, Pharmacyclics and Repros Therapeutics Yahoo! Finance, 1 week ago The Zacks Analyst Blog Highlights:Auxilium, Gilead, AbbVie, Amgen and Alnylam MoneyShow.com, 2 weeks ago
Amgen Inc. ( AMGN ) is set to report third-quarter 2014 results on Oct 27 after the market closes. Last quarter, the company had posted a positive earnings surprise of 19.10%. The company recorded positive earnings surprises in the last four ...Yahoo! Finance, 5 days ago Stock of the Week: Amgen Inc. (AMGN) Nasdaq, 3 weeks ago
(Marketintelligencecenter.com via COMTEX) -- With bearish technical indicators and a 4 STARS (out of 5) buy ranking from Standard & PooraEUR(TM)s, Amgen Inc ( AMGN ) could be an attractive play for investors according to ...TradingCharts.com, 2 weeks ago Potential Amgen (AMGN) Trade Targets 7.54% Return Individual.com, 3 weeks ago
Amgen ( AMGN ) announced that it has submitted a Biologics License Application (:BLA) to the FDA for its oncology candidate, blinatumomab. The company is looking to get the candidate approved for the treatment of adults suffering from ...Yahoo! Finance, 1 month ago Amgen One Step Closer To Immunotherapy Market Bidness Etc, 1 month ago
on your WebpageAdd Widget >Get your members hooked!